DOCSLIB.ORG

Assistance& Reimbursement Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Assistance& Reimbursement Guide ASSOCIATION OF COMMUNITY CANCER CENTERS / 2016 Patient ASSISTANCE& REIMBURSEMENT GUIDE $VVRFLDWLRQRI&RPPXQLW\&DQFHU&HQWHUV 7KLVSXEOLFDWLRQLVDEHQH¿WRIPHPEHUVKLS ASSOCIATION OF COMMUNITY CANCER CENTERS (ACCC) Steven L. D’Amato, BSPharm, BCOP President Christian Downs, JD, MHA Executive Director Monique J. Marino Manager, Publications Amanda Patton Manager, Communications Jillian Kornak Writer, Editor ABOUT THE ASSOCIATION OF COMMUNITY CANCER CENTERS The Association of Community Cancer Centers (ACCC) is the leading advocacy and education organization for the multidisciplinary cancer care team. Approximately 20,000 cancer care professionals from 2,000 hospitals and practices nationwide are affiliated with ACCC. Providing a national forum for addressing issues that affect community cancer programs, ACCC is recognized as the premier provider of resources for the entire oncology care team. Our members include medical and radiation oncologists, surgeons, cancer program administrators and medical directors, senior hospital executives, practice managers, pharmacists, oncology nurses, radiation therapists, social workers, and cancer program data managers. Not a member? Join today at accc-cancer.org/ membership or email: [email protected]. For more information, visit the ACCC website at accc-cancer.org. Follow us on Facebook, Twitter, LinkedIn, and read our blog, ACCCBuzz. ASSOCIATION OF COMMUNITY CANCER CENTERS Patient 2016 ASSISTANCE& REIMBURSEMENT GUIDE Financial Toxicity A conversation with Yousuf Zafar, MD, MHS, and Dan Sherman, MA, LPC 4 Accessing Co-Pay Assistance Opportunities By Ann Kaley Kline 10 PAP Flow Chart 16 PAP Quick Reference Guide 18 Pharmaceutical Company Patient Assistance & Reimbursement Programs AbbVie 26 IPSEN Biopharmaceuticals 54 Amgen, Inc. 27 Janssen Biotech, Inc. 56 ARIAD Pharmaceuticals, Inc. 30 Lilly Oncology 59 Astellas Pharma US, Inc. 31 Merck 62 AstraZeneca 34 Novartis Pharmaceuticals Corporation 65 Bayer HealthCare Pharmaceuticals, Inc. 36 Pfizer, Inc. 68 Boehringer Ingelheim Pharmaceuticals, Inc. 38 Pharmacyclics, LLC 72 Bristol-Myers Squibb 40 Sandoz, Inc. 73 Celgene Oncology 43 Sanofi Oncology 74 Eisai Co., Ltd. 46 Seattle Genetics 76 Genentech, Inc. 48 Taiho Oncology 78 Incyte Corporation 51 Takeda Oncology 79 Insys Therapeutics, Inc. 53 Teva Oncology 82 Other Patient Assistance Programs & Resources Agingcare.com® 83 NeedyMeds 87 BenefitsCheckUp® 83 Partnership for Prescription Assistance 87 CancerCare® 83 Patient Access Network Foundation 88 CancerCare® Co-Payment Assistance Foundation 84 Patient Advocate Foundation 89 Cancer Financial Assistance Coalition 85 RxAssist 90 Co-Pay Relief 85 RxHope™ 91 HealthWell Foundation 85 Rx Outreach® 91 The Leukemia & Lymphoma Society 86 ACCC 2016 Patient Assistance and Reimbursement Guide I accc-cancer.org / 1 Patient Assistance and Reimbursement Assistance Programs by Drug or Product Abraxane® (paclitaxel protein-bound particles) for injection 43 Leukine® (sargramostim) 74 Actiq® (oral transmucosal fentanyl citrate) [C-II] 82 Lonsurf® (trifluridine and tipiracil) tablets 78 Adcetris® (brentuximab vedotin) for injection 76 Lupron Depot® (leuprolide acetate for deposit suspension) 26 Afinitor® (everolimus) tablets 65 Lynparza® (olaparib) 34 Akynzeo® (neutpitant/palonosetron) 46 Mekinist® (trametinib) tablets 65 Alecensa® (alectinib) capsules 48 Mozobil® (plerixafor) for injection 74 Alimta® (pemetrexed for injection) 59 Neulasta® (pegfilgrastim) 27 Aloxi® (palonosetron hydrochloride) 46 Neumega® (oprelvekin) 68 Aranesp® (darbepoetin alfa) 27 Neupogen® (filgrastim) 27 Arimidex® (anastrozole) 34 Nexavar® (sorafenib) tablets 36 Aromasin® (exemestane) tablets 68 Ninlaro® (ixazomib) capsules 79 Avastin® (bevacizumab) 48 Nplate® (romiplostim) 27 Bendeka™ (bendamustine hydrochloride) for injection 82 Odomzo® (sonidegib) 65 Blincyto™ (blinatumomab) 27 Opdivo® (nivolumab) 40 Bosulif® (bosutinib) tablets 68 Perjeta™ (pertuzumab) 48 Camptosar® (irinotecan hydrochloride injection) 68 Pomalyst® (pomalidomide) 43 Caprelsa® (vandetanib) 34 Portrazza™(necitumumab) 59 Casodex® (bicalutamide) 34 Procrit® (epoetin alfa) 56 Cotellic™ (cobimetinib) tablets 48 Prolia® (denosumab) 27 Cyramza® (ramucirumab) 59 Promacta® (eltrombopag) tablets 65 Darzalex™ (daratumumab) 56 Revlimid® (lenalidomide) 43 Doxil® (doxorubicin HCl liposome injection) 56 Rituxan® (rituximab) 48 Elitek® (rasburicase) 74 Sandostatin® (octreotide acetate) for injection 65 Ellence® (epirubicin hydrochloride injection) 68 Sandostatin LAR® Depot (octreotide acetate 65 Eloxatin® (oxaliplatin) for injection 74 for injectable suspension) Emcyt® (estramustine phosphate sodium capsules) 68 Sensipar® (cinacalcet) 27 Emend® (aprepitant) 62 Somatuline® Depot (lanreotide) for injection 54 Emend® (fosaprepitant dimeglumine) for injection 62 Sprycel® (dasatinib) 40 Empliciti™ (elotuzumab) 40 Stivarga® (regorafenib) tablets 36 Epogen® (epoetin alfa) 27 Subsys® (fentanyl sublingual spray) 53 Erbitux® (cetuximab) 40, 59 Sutent® (sunitinib malate) 68 Erivedge™ (vismodegib) 48 Sylatron™ (peginterferon alfa-2b) for injection 62 Exjade® (deferasirox) tablets 65 Sylvant® (siltuximab) 56 Farydak™ (panobinostat) capsules 65 Synribo® (omacetaxine mepesuccinate) for injection 82 Faslodex® (fulfestrant) 34 Tafinlar (dabrafenib) capsules 65 Femara® (letrozole) tablets 65 Tagrisso® (osimertinib) 34 Fentora® (fentanyl buccal tablet) [C-II] 82 Tarceva® (erlotinib) 31, 48 Gardasil (Quadrivalent Human 62 Tasigna® (nilotinib) tablets 65 Papillomavirus Recombinant Vaccine) Taxotere® (docetaxel) for injection 74 Gardasil®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) 62 Thalomid® (thalidomide) 43 Gazyva™ (obinutuzumab) 48 Thymoglobulin® (anti-thymocyte globulin [rabbit]) 74 Gemzar® (gemcitabine hydrochloride) 59 Temodar® (temozolomide) 62 Gilotrif™ (afatinib) 38 Gleevec® (imatinib mesylate) tablets 65 Torisel® (temsirolimus) for Injection 68 Granix™ (tbo-filgrastim) for injection 82 Treanda® (bendamustine HCl) for injection 82 Halaven™ (eribulin mesylate) 46 Trisenox® (arsenic trioxide) for injection 82 Herceptin® (trastuzumab) 48 Tykerb® (lapatinib) tablets 65 Hexalen® (altretamine) capsules 46 Vectibix® (panitumumab) 27 Ibrance® (palbociclib) 68 Velcade® (bortezomib) for injection 79 Iclusig™ (ponatinib) 30 Vidaza® (azacitidine) 43 Idamycin® (idarubicin hydrochloride) for injection 68 Votrient™ (pazopanib) tablets 65 Imbruvica® (ibrutinib) 72 Xalkori® (crizotinib) capsules 68 Imlygic™ (talimogene laherparepvec) 27 Xeloda® (capecitabine) 48 suspension for intralesional for injection Xgeva™ (denosumab) 27 Inlyta® (axitinib) tablets 68 Xofigo® (radium Ra 223 dichloride injection) 36 Intron® A (interferon alfa-2b, recombinant) for injection 62 Xtandi® (enzalutamide) capsules 31 Iressa® (gefitinib) 34 Yervoy® (ipilimumab) 40 Istodax® (romidepsin) for injection 43 Yondelis® (trabectedin) 56 Ixempra™ (ixabepilone) 40 Zaltrap® (ziv-aflibercept) 74 Jadenu™ (deferasirox) tablets 65 Zarxio™ (filgrastim-sndz) 73 Jakafi® (ruxolitinib) tablets 51 Zelboraf® (vemurafenib) 48 Jevtana® (cabazitaxel) 74 Zinecard® (dexrazoxane) for injection 68 Kadcyla® (ado-trastuzumab emtansine) 48 Zoladex® (goserelin acetate) 34 Keytruda® (pembrolizumab) 62 Zolinza® (vorinostat) 62 Kyprolis® (carfilzomib) for injection 27 Zykadia™ (ceritinib) capsules 65 Lenvima™ (lenvatinib) capsules 46 Zytiga® (abiraterone acetate) 56 2 / ACCC 2016 Patient Assistance and Reimbursement Guide I accc-cancer.org TABLE OF CONTENTS Financial Toxicity: A conversation with Yousuf Zafar, MD, MHS, and Dan Sherman, MA, LPC Dr. Zafar. My primary goal is to make sure that any treatment I provide a patient first does no harm. Traditionally, we’ve thought about harm wareness has grown among both the as physical harm, the physical side effects that patients public and providers about the risks can experience as a result of treatment. More and more, of financial toxicity for patients with however, financial harm has to be a part of that con- cancer and their families. At the same sideration as well. So as an oncologist, if I’m prescribing time, as healthcare reform evolves, a treatment for a patient, considering both the poten- Aunderstanding the financial implications of care has tial for physical and financial harms is well within become increasingly complex. ACCC asked members my purview. of the Financial Advocacy Network (FAN) Advisory Committee Yousuf Zafar, MD, MHS, associate professor How do you think providers can do a better of Medicine, Duke Cancer Institute, and Dan Sherman, job in this area? MA, LPC, clinical financial consultant, The Lacks Cancer Center, to share their perspectives on why addressing QDr. Zafar. I think the first step is engaging patients on financial concerns with cancer patients is important the topic. There is evidence that just discussing finan- and how the role of financial counselors is evolving. cial harm or financial toxicity with their doctor can reduce the distress that patients feel. So really what this Why is it important that we do a better job means is that patients like to know that they and their of helping patients with financial issues doctor are on the same page when it comes to what the related to their cancer treatments? patient is experiencing. That’s the first step. The second Q is being aware of the resources around us that can help. As an oncologist I don’t think my job is to know how 4 / ACCC 2016 Patient Assistance and Reimbursement Guide I accc-cancer.org TABLE OF CONTENTS ...if I’m prescribing a treatment for a patient, considering
Load more

Recommended publications
  • Medical Loss Ratio Regulation in the Pharmaceutical Industry
    BYU Law Review Volume 2018 Issue 1 Article 8 Fall 8-31-2018 Leveraging Pharma to Lower Premiums: Medical Loss Ratio Regulation in the Pharmaceutical Industry Cami R. Schiel Follow this and additional works at: https://digitalcommons.law.byu.edu/lawreview Part of the Law Commons, and the Pharmaceutical Preparations Commons Recommended Citation Cami R. Schiel, Leveraging Pharma to Lower Premiums: Medical Loss Ratio Regulation in the Pharmaceutical Industry, 2018 BYU L. Rev. 205 (2018). Available at: https://digitalcommons.law.byu.edu/lawreview/vol2018/iss1/8 This Comment is brought to you for free and open access by the Brigham Young University Law Review at BYU Law Digital Commons. It has been accepted for inclusion in BYU Law Review by an authorized editor of BYU Law Digital Commons. For more information, please contact [email protected]. 5.SCHIEL_FIN_NOHEADER.DOCX (DO NOT DELETE) 8/17/18 10:42 AM Leveraging Pharma to Lower Premiums: Medical Loss Ratio Regulation in the Pharmaceutical Industry Many recognize escalating drug prices as a significant dilemma related to America’s rising healthcare costs. Yet few can agree on what to do about them. Unaffordable drug prices are a result of many complex forces. One theory to address this problem is to reduce all government intervention and let normal market forces act as they usually do to bring the goods’ prices down to consumer-friendly ranges. However, the pre- scription drug market is not, and perhaps never can be, a normal market. Reasons for this include (1) a lack of price transparency, (2) information and control asymmetries between patients and physicians, (3) third-party payors, (4) demand that remains constant irrespective of any exorbitant price increases (i.e., market inelasticity), and (5) patent-ensured mono- polies.
    [Show full text]
  • Price Gouging the American Public
    The Pharma Big 10: Price Gougers, Tax Dodgers DecemberNovemb e2017r 2017 THE PHARMA BIG 10: PRICE GOUGERS, TAX DODGERS CREDITS Authors William Rice, senior writer, Kayla Kitson, senior researcher, and Frank Clemente, executive director, Americans for Tax Fairness Research Americans for Tax Fairness: William Rice and Kayla Kitson. Institute on Taxation and Economic Policy for corporate financial and tax data: Richard Phillips, senior policy analyst, and Matthew Gardner, senior fellow. Special thanks to Open Society Foundations for a generous grant in support of this work and to Azzi Momenghalibaf, senior program officer with the Open Society Public Health Program. Special thanks to Leigh Purvis at AARP Public Policy Institute for providing prescription-drug retail price data. Report design by Katie Vann Americans for Tax Fairness is a diverse coalition of 425 national and state endorsing organizations that collectively represent tens of millions of members. The organization was formed on the belief that the country needs comprehensive, progressive tax reform that results in greater revenue to meet our growing needs. ATF is playing a central role in Washington and in the states on federal tax-reform issues. Americans for Tax Fairness 1101 17th Street NW, Suite 301 Washington, D.C. 20036 www.AmericansForTaxFairness.org Table of Contents Introduction & Key Findings ...................................................................................................... 4 Pharma Big 10 Price Gouging ............................................................................................... 6 Figure 1: Increase in Select Prescription Drug Prices for Medicare, Medicaid & Retail Customers, 2011—2015 .. 7 Table 1: Price Increases on Selected U.S. Prescription Drugs Purchased Through Medicare, 2011-2015 ............ 8 Table 2: Price Increases on Selected U.S. Prescription Drugs Purchased Through Medicaid, 2011-2015 ...........
    [Show full text]
  • Medical Loss Ratio Regulation in the Pharmaceutical Industry Cami R
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Brigham Young University Law School BYU Law Review Volume 2018 | Issue 1 Article 8 Fall 8-31-2018 Leveraging Pharma to Lower Premiums: Medical Loss Ratio Regulation in the Pharmaceutical Industry Cami R. Schiel Follow this and additional works at: https://digitalcommons.law.byu.edu/lawreview Part of the Law Commons, and the Pharmaceutical Preparations Commons Recommended Citation Cami R. Schiel, Leveraging Pharma to Lower Premiums: Medical Loss Ratio Regulation in the Pharmaceutical Industry, 2018 BYU L. Rev. 205 (2018). Available at: https://digitalcommons.law.byu.edu/lawreview/vol2018/iss1/8 This Comment is brought to you for free and open access by the Brigham Young University Law Review at BYU Law Digital Commons. It has been accepted for inclusion in BYU Law Review by an authorized editor of BYU Law Digital Commons. For more information, please contact [email protected]. 5.SCHIEL_FIN_NOHEADER.DOCX (DO NOT DELETE) 8/17/18 10:42 AM Leveraging Pharma to Lower Premiums: Medical Loss Ratio Regulation in the Pharmaceutical Industry Many recognize escalating drug prices as a significant dilemma related to America’s rising healthcare costs. Yet few can agree on what to do about them. Unaffordable drug prices are a result of many complex forces. One theory to address this problem is to reduce all government intervention and let normal market forces act as they usually do to bring the goods’ prices down to consumer-friendly ranges. However, the pre- scription drug market is not, and perhaps never can be, a normal market.
    [Show full text]
  • PRESCRIPTION DRUG COUPON STUDY Report to the Massachusetts Legislature JULY 2020
    COMMONWEALTH OF MASSACHUSETTS HEALTH POLICY COMMISSION PRESCRIPTION DRUG COUPON STUDY Report to the Massachusetts Legislature JULY 2020 EXECUTIVE SUMMARY In this report, required by Chapter 363 of the 2018 Session Prescription drug coupons are currently allowed in all 50 Laws, the Massachusetts Health Policy Commission (HPC) states for commercially-insured patients. Federal health examines the use and impact of prescription drug coupons insurance programs, such as Medicare, Medicaid, Tricare in Massachusetts. This report focuses on coupons issued by and Veteran’s Administration, prohibit the use of coupons pharmaceutical manufacturers that reduce a commercial based on federal anti-kickback statutes. Massachusetts patient’s cost-sharing. Prescription drug coupons are offered became the last state to authorize commercial coupon use almost exclusively on branded drugs, which comprise only in 2012 but continues to prohibit manufacturers from 10% of all prescriptions dispensed in the U.S., but account offering coupons and discounts on any prescription drug for 79% of total drug spending. Despite the immediate ben- that has an “AB rated” generic equivalent as determined efit of drug coupons to patients, policymakers and experts by the Food and Drug Administration (FDA). The 2012 debate whether and how coupons should be allowed in the law authorizing coupons in Massachusetts also contained commercial market given the potential relationship between a sunset provision, under which the law would have been coupon usage and increased spending on branded drugs repealed on July 1, 2015. However, this date of repeal versus lower cost alternatives. was postponed several times and ultimately extended to January 1, 2021. Massachusetts has long sought to con- Coupons reduce or eliminate the patient’s cost-sharing sider the impact of drug coupons on the Commonwealth’s responsibility required by the patient’s insurance plan, while landmark cost containment goals, as well as the benefits for the plan’s costs for the drug remain unchanged.
    [Show full text]
  • Physicians' Attitudes About Prescribing and Knowledge of The
    ORIGINAL INVESTIGATION Physicians’ Attitudes About Prescribing and Knowledge of the Costs of Common Medications Steven Reichert, MD; Todd Simon, MD; Ethan A. Halm, MD, MPH Background: Compliance with medical therapy is of- only 13% had been formally educated about drug costs. ten compromised because patients cannot afford to pay Regarding insurance coverage, 94% of physicians gave for medications. Inadequate physician knowledge of drug strong consideration to the cost of medications when pa- costs may unwittingly contribute to this problem. tients were self-paying, 68% when patients had Medi- care, and 30% when patients had Medicaid or were par- Objective: To measure attitudes about prescribing and ticipants in a health maintenance organization with a knowledge of medication costs and compare differences prescription plan. Physicians’ estimates of the cost of a among attending physicians and residents. month’s supply of 33 commonly used medications were accurate in 45% of cases, too low for 40%, and too high Design/Participants: Written survey of internal medi- for 15%. The costs of brand-name and expensive drugs cine house staff and general medicine attending physi- were most likely to be underestimated. House officers were cians in an urban hospital-based primary care center. less cost-conscious than attending physicians. Results: One hundred thirty-four of 189 physicians re- Conclusions: Physicians were predisposed to being sponded (71% response rate). Seventy percent of respon- cost-conscious in their prescribing habits, but lacked dents were house officers and 30% were attending phy- accurate knowledge about actual costs and insurance sicians. Eighty-eight percent of physicians felt the cost coverage of drugs.
    [Show full text]
  • Prices of Diabetes Drugs for Seniors and the Uninsured in the United States and Abroad
    Prices of Diabetes Drugs for Seniors and the Uninsured in the United States and Abroad California’s 44th Congressional District Staff Report Committee on Oversight and Reform U.S. House of Representatives April 2019 oversight.house.gov EXECUTIVE SUMMARY More than 30 million people in the United States, including more than one in four seniors, have diabetes. Patients with diabetes rely on prescription drugs, including insulin, to help manage their conditions. Over the past two decades, manufacturers have systematically and dramatically raised the prices of their insulin products by more than tenfold—often in lockstep. These high prices lead many people to ration or stop taking their medications, which can result in serious health complications and even death, as the Committee heard in direct testimony earlier this year. The prices of diabetes medications—and insulin in particular—are far higher in the United States than they are overseas, in part because certain federal programs lack the authority to negotiate directly with drug manufacturers. In order to assess the impact of the high prices of diabetes medications on seniors and uninsured patients, this report was prepared by the staff of the House Committee on Oversight and Reform for the 44th Congressional District of California. Costs to Seniors and Medicare This report estimates that there are approximately 17,000 Medicare beneficiaries in the district who have been diagnosed with diabetes. The 50 most popular brand-name diabetes medications used by these beneficiaries are available at significantly lower prices in other countries. For example, the cost of these drugs to the Medicare program in the district are 4.3 times the cost in Australia, 3.3 times the cost in the United Kingdom, and 2.5 times the cost in Canada.
    [Show full text]
  • Patient Cost-Saving Guide at Caremount Medical, Our Primary Focus Is Delivering High-Quality Care That Improves Our Patient’S Experience and Health
    MEDICATION RESOURCES Patient Cost-Saving Guide At CareMount Medical, our primary focus is delivering high-quality care that improves our patient’s experience and health. Since exceptional care is our objective, we understand prescribed treatments may not always be covered by your specific insurance plan. CONTACT US We do our best to provide alternatives when applicable and available. We WEB: caremountmedical.com encourage you to work with your insurance company to verify coverage If you would like to speak to someone in order to avoid any unexpected costs. Most plans provide a PHONE: formulary about your care, please contact our Care (preferred drug list), and can advise of lower cost alternatives if the specific Coordination Team: (845) 202-6340 drug you are prescribed is not covered. Always speak with your doctor first to confirm if the alternative may be appropriate for your care and CAREMOUNT PATIENT ASSISTANCE TEAM: condition. (914) 440-2840 With prescription drugs costs continuing to rise, we wanted to provide you MEDICARE PATIENTS: Contact Medicare with a resource to take advantage of certain cost saving programs that are at 1-800-633-4273 available to help offset any medication costs. Please see the list below for a Or reach out to your Part D prescription drug quick reference guide to possible cost saving resources. plan to verify any specific benefits and coverage. Resource Contact About Some pharmaceutical companies offer assistance programs for the drugs they AstraZeneca, Merck, manufacture. See their website to review Drug manufacturer assistance programs Novartis, Pfizer, etc. any eligibility criteria. Medicare and Social Security offer a program Extra Help (800) 772-1213 to reduce Part D plan premiums and copays for those for qualify.
    [Show full text]
  • Affordability Options for Prescription Drugs
    Affordability Options for Prescription Drugs In recent years healthcare choices have expanded significantly, many due to advances in pharmaceutical treatments. Although prescription drug expense represents only a small portion of total U.S. healthcare spending1, the out-of-pocket costs for individual patients can be significant. This tool highlights some of the resources that are available to assist patients with their prescription drug costs and correlates the options with primary insurance status. This resource is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Laws, regulations, and policies concerning reimbursement are complex and are updated frequently. While we have made an effort to be current as of the publication date, the information may not be as current or comprehensive when you view it. In addition, this information does not represent any statement, promise or guarantee by Johnson & Johnson Health Care Systems Inc. about coverage, levels of reimbursement or payment. Please consult with your payer organization(s) for local or actual coverage and reimbursement policies and determination processes. Please consult with your counsel or reimbursement specialist for any reimbursement or billing questions specific to your institution. 1. Prescription drugs represented 10% of total health care spending in 2010; Source: National Center for Health Statistics. (2013). Health, United States, 2012; Table 113. Available at: http://www.cdc.gov/nchs/data/hus/hus12.pdf#113. 1 Options Options
    [Show full text]
  • Excessive Pricing of Off-Patent Pharmaceuticals: Hatch It Or Ratchet?
    39546-nyu_92-4 Sheet No. 194 Side B 10/12/2017 08:00:42 \\jciprod01\productn\N\NYU\92-4\NYU412.txt unknown Seq: 1 11-OCT-17 15:35 EXCESSIVE PRICING OF OFF-PATENT PHARMACEUTICALS: HATCH IT OR RATCHET? JENNIFER L. GRABER* There is growing concern over the pharmaceutical industry’s ability to set and raise drug prices as it sees fit. The price of a drug that has not been protected by a patent for decades can suddenly increase—or “ratchet”—as much as 10,000%. This Note identifies the problem of ratcheting drug prices and considers whether these abrupt changes in drug prices derive from a longstanding problem inherent in the United States’ pharmaceutical regulatory regime. It then considers the most commonly sug- gested mechanism for countering high drug prices—stimulating competition in the pharmaceutical market—but ultimately concludes that focusing solely on increasing competition constructs an overly simplistic view of ratcheting drug prices. In order to find an effective solution to unexpected increases in drug prices, this Note evaluates a small subset of pharmaceuticals that have recently undergone a sudden price increase and separates the ratcheting events into two categories: (1) those that occur as a result of natural deviations in the market, and (2) those that occur due to business tactics that take advantage of vulnerabilities in the drug market. It concludes that under this categorization, antitrust law may provide an effective solution specifically directed at ratcheting events of the second category— those driven by anticompetitive behavior. INTRODUCTION ................................................. 1147 R I. THE RISE OF DRUG PRICES AND THE LAWS THAT REGULATE PRICING....................................
    [Show full text]
  • State Efforts to Lower Consumer Cost-Sharing for High-Cost Prescription Drugs Stakeholder Perspectives
    HEALTH POLICY CENTER State Efforts to Lower Consumer Cost-Sharing for High-Cost Prescription Drugs Stakeholder Perspectives Sandy Ahn and Sabrina Corlette GEORGETOWN UNIVERSITY HEALTH POLICY INSTITUTE August 2017 Federal action to lower the cost of prescription drugs has broad support across the political spectrum. In one recent poll, over 60 percent of Americans identified lowering the cost of prescription drugs as a “top priority” for the Trump administration and Congress (Kirzinger et al. 2017). But to date, there has been little change in federal policy on drug pricing and costs. Perhaps in response to federal inaction on this issue, state legislators have introduced 80 bills in 2017 alone that attempt to lower prescription drug costs. One area of focus for states has been high out-of-pocket drug costs for consumers with chronic conditions such as multiple sclerosis or cancer that require treatment with specialty drugs. California, Colorado, Delaware, Louisiana, Maryland, Montana, New York, and Vermont have leveraged their authority to regulate health insurance to lower cost-sharing charges for consumers using these specialty drugs. To assess the goals and impact of these state policies, we conducted interviews with regulators, insurers, and consumer advocacy groups in four of the eight states: California, Colorado, Louisiana, and Montana. Most of the stakeholders said that these state policies have had their intended impact by reducing consumers’ out-of-pocket costs for expensive prescription drugs and by preventing insurers from discriminating against high-cost enrollees through the design of plan formularies. However, stakeholders had mixed opinions about the policies. Insurer respondents noted that they shift costs to other consumers, either through higher premiums or cost-sharing for other services, and mask the larger problem of escalating drug prices.
    [Show full text]
  • Nine Ways to Deal with Escalating Drug Costs
    Nine Ways to Deal with Escalating Drug Costs By Keith Loria Nov 7, 2018 As drug costs continue to increase at an unsustainable rate, many industry insiders believe the current trajectory of pharmaceutical expenses will eventually bankrupt the U.S. healthcare system. Girish Dighe, PharmD, MS, director of pharmacy, business services, at OhioHealth, a not-for- profit system of hospitals and healthcare providers in Columbus, notes that there are fundamental flaws within the healthcare system causing vastly complex challenges to drug pricing. “The multitude of stakeholders involved in the drug channels for bringing patients access to medications (manufacturers, insurers, pharmacy benefit managers (PBMs), providers, retail pharmacies, wholesalers) revolves around financial incentives driving each stakeholder,” Dighe says. “The growing spread between pharmaceutical list price and net price negotiated by drug channel stakeholders has negatively impacted patients’ out-of- pocket costs.” According to a recent survey from NORC at the University of Chicago and the West Health Institute, 77% of Americans believe prescription drug prices are unreasonably high. President Donald Trump took a big stance against rising drug prices early in his tenure and since then some drug companies—Pfizer, Novartis, Sanofi, Roche, and Merck among them—have announced that they’re freezing or even lowering drug costs. Alex Azar, HHS secretary, recently announced that the administration is also working to stop drug rebates to PBMs. The Pharmaceutical Care Management Association (PCMA), which represents pharmacy benefit managers, issued a report recently blaming high drug prices on drug makers, not PBMs. In the report, Mark Merritt, PCMA’s president and CEO, said the findings supported the belief that drug makers set and raise prices unrelated to the rebates they negotiate with PBMs.
    [Show full text]
  • Patient Access to Care and Treatments in the Cost-Shifting Era
    LEAD AUTHOR: Ralph D. McKibbin, MD, FACP, FACG, AGAF PATIENT ACCESS TO CARE AND TREATMENTS IN THE COST-SHIFTING ERA: Preserving the Patient-Provider Decision-Making Relationship A COLLABORATIVE PROJECT OF THE DIGESTIVE DISEASE NATIONAL COALITION TABLE OF CONTENTS 3 The Problem 4 Background 5 Common Medication and Medical Supply Utilization Programs and Cost-Shifting Tactics 5 Quantity Limits 5 Step Therapy 7 Medication Tiers 7 Non-Medical Switching for Drug Treatments 8 Non-Medical Switching for Medical Supplies 10 Prior Authorization 11 Cost Shifting and Co-Pay Accumulator Adjustment Programs 12 The Path to Improvement 13 The Basis for Change 13 Clinical Validity 13 Continuity of Care 14 Transparency and Fairness 14 Timely Access and Administrative Efficiency 14 Alternatives and Exemptions 15 Going Forward 15 The Coalition 15 Mission 15 Digestive Diseases 15 White Paper Review Panel 16 DDNC Constituent Members 16 DDNC Institutional Members 17 Literature Review Patient Access to Care and Treatments in the Cost-Shifting Era 2 The Problem The patient-provider relationship is the cornerstone of quality healthcare. A 2017 survey from the Council of Accountable Physician Practices (CAPP) found that consumers believe patient-provider relationships are the single most important factor in quality care.1 Through shared decision-making the patient and provider will develop a plan of care which meets their needs and expectations. Care guidelines are often used to establish safe and effective therapeutic plans. However, even peer reviewed guidelines acknowledge limitations and the need to individualize treatment decisions. Patients with rare, complex, and chronic diseases often need high-cost specialty medications to manage their conditions and maintain their health.
    [Show full text]